and discrimination and became a leading champion of equity and diversity in the scientific community. And he was a devoted and beloved mentor to young scientists. I had the great fortune of being friends with Ben for almost three decades. Like so many who knew him, I will always be inspired by his originality, optimism, generosity, and courage-I am heartbroken that he is no longer with us.
Ben initially trained in medicine. Born and raised in New Jersey, he earned a bachelor's degree from MIT, attended medical school at Dartmouth, and completed a residency in neurology at Weill Cornell Medical College. There, he grew frustrated with our inability to treat neurodegenerative disorders, so he decided to refocus his career on research and entered the PhD program at Harvard Medical School.
It's there that Ben chose to focus on glia. As a neurologist examining degenerating brain tissue, he had been struck by the presence of reactive glia in close association with brain lesions, which got him interested in glia as potential players in disease. But a second motivation ties back to his originality. He simply couldn't accept that such a prominent cell type, with diverse and dynamic morphologies, would just be support material for neurons, and he made the bet that they would have unappreciated and more important roles-perhaps in physiology, development, regeneration, or degeneration. He bet big-his entire career, in fact-and the bet paid off on all fronts.
It is worth remembering that when Ben started his PhD in the early '80s, the study of glia was a niche enterprise and that most neuroscientists focused on neurons, but fortunately, Ben found mentors in Linda Chun and in David Corey, whose lab he joined, who supported him in his passion. Ben's vision and independence so early in his career were unusual, to say the least.
Every great scientist has a distinctive scientific style. Ben's approach, already evident in his PhD work, was systematic cellular reductionism. He believed that isolating specific types of glia and neurons from embryonic and adult tissues as gently as possible would enable him first to understand the properties of individual cells and, by culturing different cell types together, also to learn how one type influences another's behavior or function. It was natural that Ben elected to perform postdoctoral work with Martin Raff, who had pioneered this type of approach with glial progenitor cells. The approach was so central to how Ben did science that throughout his career he continually worked to improve methods for cell purification and characterization.
From this approach emerged a steady flow of discoveries. Many significantly extended existing notions of glial function, including his doctoral finding that the electrical properties of many glial types didn't fit with prevailing models, and his postdoctoral finding that proliferation of the precursors to glial cells that myelinate axons (so-called oligodendrocytes) is controlled by the axons they ensheath.
But many discoveries, particularly with his trainees at Stanford University where he established his laboratory, also went much further and radically altered how we think of glia.
For example, their surprising finding that retinal ganglion cells cultured alone make many fewer synapses than when cultured with glia called astrocytes led them to isolate several families of synaptogenic proteins secreted by astrocytes that are required for synapse development and function in the brain.
In another example, they unexpectedly found that postnatal neurons co-cultured with immature astrocytes make C1q, the initiating protein in the classical complement cascade, which led them to discover that C1q is localized to synapses in early postnatal life and functions to direct pruning of extraneous synapses by microglia, a process that is aberrantly reactivated in models of neurodegenerative disease.
In a third example, the isolation and characterization of reactive astrocytes from brain-injured mice led them to define two broad classes, A1 and A2, and to show that A1 astrocytes are induced by inflammatory microglia, accumulate in neurodegenerative disorders, and secrete neurotoxic factors that contribute to death of injured neurons.
These examples, three among many, are all vintage Barres. In each case, the starting point was careful analysis of purified cell types alone and together, leading to discovery of unexpected cellular phenomena, which were in turn mined through clever detective work for molecular insights, culminating in novel principles, including previously unsuspected roles for astrocytes in synapse formation, for microglia in synaptic pruning, and for reactive astrocytes in neurodegeneration.
In each case, the analysis also provided entry points to tackle disease. And none of this came easily: in every case, it was necessary to overcome skepticism through rigorous analysis-and sheer determination.
It was also very much in character that Ben encouraged his trainees to take these exciting projects with them when they set up their own laboratories. He was unfailingly generous, always prepared to start anew when a project migrated with a trainee to a new home. In this way, Ben kept tackling new problems and simultaneously spawned a legacy of talented young scientists who today are advancing the field at top institutions around the world.
Ben was also a devoted member of the Stanford community, served as department chair, and had a special interest in education. He feared in particular that translation of scientific discoveries into medical advances was being impeded by the paucity of basic scientists who are knowledgeable about human biology and disease, so he championed a novel Master of Medicine program that enables PhD students to acquire such knowledge without having to become clinicians.
It was also at Stanford that Ben yet again drew on the fonts of courage that had been evident in his scientific career but now applying them to his own life as he decided to transition from female to male, from Barbara to Ben, a decision he discussed candidly throughout his life. He has described how, as a child, he never felt comfortable being identified as a girl, and how, in his 40s, he read a news article about a transgender man and only then ''realized there were other people out there like me.'' Those of us who were fortunate enough to be Ben's friends at the time were privileged that he shared the experience of his transition with us.
His transition provided Ben with a unique vantage point, and he was shocked at how differently he was treated as a man than he had been as a woman. In a particularly memorable example, he once overheard an audience member say that ''Ben Barres gave a great seminar today, but then his work is much better than his sister's''-not realizing they were the same person. Experiences like that highlighted further for him the bias and sexism permeating the scientific community and drove him to become an outspoken advocate for underrepresented groups in science, including women, members of the LGBT community, and people of color. For well over a decade, he was an extraordinary spokesperson and role model. Two years ago, Ben's courage was called upon once more when he was diagnosed with metastatic cancer. He combated his illness with the same determination with which he tackled all challenges in his life and didn't let it interfere. He continued to advance his science, including publishing his breakthrough A1 astrocyte discovery; he continued to be a vocal advocate for equity in science; and he continued to make time for friends and colleagues.
Above all, he continued to focus on the well-being of his students and postdoctoral fellows, making sure that each had another mentor to fall back on, that their manuscripts were submitted, that letters of recommendation were in order.
The last email I received from Ben, just hours before he passed, concerned two of his fellows who are on the job market. Until the very end, he put others first.
It is said that the measure of a person is in how they deal with adversity. Ben consistently tackled the great challenges of his life with courage and with grace. In his final months, he continually focused on the positive, expressing gratitude for all that he had been able to experience and contribute. His only regret, he said, is that he wouldn't be able to learn the outcome of experiments that excited him. Ben's zest for science and for life, his deep humanity and courage, are shining inspirations.
He helped make the world a better place, and he has forever enriched our lives.
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